Professor and Chair, Dermatology, Tufts Medical Center
Dermatology
Dr. Alice B. Gottlieb, MD
|
|
Give Review
Alice B. Gottlieb, MD is an expert in the field of Dermatology. She went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18/49 in Research/PrimaryCare. She over the years received 11 awards: "America's Top Doctors", "Boston Magazine", "CMS Meaningful Use Stage 1 Certification", "New York Magazine: Top Doctors", "Top Doctors: New York Metro Area", "New Jersey Monthly: Top Doctors", "Fellow", "Fellow (FAAD)", "Fellow (FACR)", "Super Doctor" and "Whos Who in Medicine and Healthcare". Alice Gottlieb is also a published physician. She has 101 paper published. The most recent paper is: Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. She accepts Medicare payments and is registered with Medicare.gov.
Publications
- Translating psoriasis guidelines into practice: Important gaps revealed.
- Secukinumab improves patient-reported psoriasis symptoms of itching, Pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.
- Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with Chronic plaque psoriasis.
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
- WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessm...
- Treatment of coexistent psoriasis and lupus Erythematosus.
- The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology.
- Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic Arthritis: a systematic review.
- Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy int...
- A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort.
- The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting.
- Apremilast for the treatment of psoriatic Arthritis.
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic Arthritis: results of an integrated analysis...
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic Arthritis despite conventional non-biological and biol...
- Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
- Ustekinumab in the treatment of psoriatic Arthritis: latest findings and clinical potential.
- Research gaps in psoriasis: Opportunities for future studies.
- Noninfectious Granulomatous dermatitides: a review of 8 disorders (Part 1 of 3).
- Long-term safety of ustekinumab for psoriasis.
- Prevalence of the Metabolic Syndrome in Children with Psoriatic Disease.
- Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom sever...
- Outcome Measures for Psoriasis Severity: A Report from the GRAPPA 2012 Annual Meeting.
- Ustekinumab improves Arthritis-related and skin-related quality of life in patients with active psoriatic Arthritis: patient reported outcomes from randomized and doub...
- NF-κB: An essential transcription factor in psoriasis.
- Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab.
- A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
- Association between pediatric psoriasis and the metabolic Syndrome.
- Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis.
- Consensus guidelines for the management of plaque psoriasis.
- The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label...
- Etanercept: efficacy and safety for approved indications.
- A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis.
- Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis.
- Management of psoriatic Arthritis from the view of the dermatologist.
- Assessor-Blinded Study of the Metabolic Syndrome and Surrogate Markers of Increased Cardiovascular Risk in Children With Moderate-to-Severe Psoriasis Compared With Age...
- Physician performance measurement: Tiered networks and dermatology (An opportunity and a challenge).
- Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
- Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
- Paraneoplastic dermatoses associated with gynecologic and breast malignancies.
- Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions.
- Comorbidities in patients with psoriasis.
- Guidelines of care for the management of psoriasis and psoriatic Arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditiona...
- Current biologic treatments for psoriasis.
- Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.
- Manifestations of cutaneous sarcoidosis: a case report of an African American woman.
- Guidelines of care for the management of psoriasis and psoriatic Arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical th...
- Skin equivalent and natural killer Cells: a new model for psoriasis and GVHD.
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic Arthritis: randomised, double-blind, placebo-controlled, crossover trial.
- Successful treatment of disseminated Granuloma annulare with adalimumab.
- Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
- Dermatomyositis induced by drug therapy: a review of case reports.
- A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
- Refractory dissecting Cellulitis of the scalp treated with adalimumab.
- Psoriasis and the metabolic Syndrome.
- Unilateral facial paralysis after treatment of secondary syphilis.
- New viral vaccines for dermatologic disease.
- Successful treatment of Hailey-Hailey disease with acitretin.
- Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
- Tumor necrosis factor blockade: mechanism of action.
- Mechanisms of action of etanercept in psoriasis.
- Structural-functional relationships of TNF-alpha antagonists: next steps.
- An open-label study to evaluate the transition of patients with Chronic plaque psoriasis from cyclosporine to alefacept.
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
- Ability to develop rhus allergic contact Dermatitis in a patient with psoriasis receiving etanercept.
- An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
- Etanercept induces apoptosis of dermal dendritic Cells in psoriatic plaques of responding patients.
- Induction of Lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.
- Psoriasis and psoriatic Arthritis: clinical features and disease mechanisms.
- Relapse, rebound, and psoriasis adverse events: an advisory group report.
- Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
- A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for ...
- Safety of efalizumab in patients with moderate to severe Chronic plaque psoriasis: review of clinical data. part II.
- Safety and efficacy of alefacept in elderly patients and other special populations.
- Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with Atopic dermatitis--a multicenter, 3-week, open-label s...
- TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
- Tacrolimus ointment is safe and effective in the treatment of Atopic dermatitis: results in 8000 patients.
- Treatment of palmoplantar psoriasis with intramuscular alefacept.
- Therapeutic options in the treatment of psoriasis and Atopic dermatitis.
- Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
- Biologic treatments for psoriasis.
- Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.
- A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
- Alefacept is well tolerated in patients with Chronic plaque psoriasis.
- Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
- The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
- Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
- Etanercept therapy for patients with psoriatic Arthritis and concurrent hepatitis C virus infection: report of 3 cases.
- Common clinical features and disease mechanisms of psoriasis and psoriatic Arthritis.
- FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
- An open trial of climatotherapy at the Dead Sea for patch-stage mycosis fungoides.
- Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
- Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
- Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.
- A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of Acne vulgaris.
- Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances.
- A randomized trial of etanercept as monotherapy for psoriasis.
- CD4+ T-Cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.
- A case of familial psoriasis with predominant hand involvement.
- Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation.
- Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic Arthritis.
Schools
Joan Sanford I Weill Medical College Of Cornell University
New York Hospital
Hospital For Special Surgery
Procedures Preformed
- Destruction of Benign Skin Lesion
- Destruction of Penile Lesion
- Steroid Injection
Conditions Treated
- Acanthosis Nigricans
- Acne
- Actinic Keratosis
- Amyloidosis
- View All
Doctors Specialties
- Rheumatology
- Dermatology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- CMS Meaningful Use Stage 1 Certification
- New York Magazine: Top Doctors
- Top Doctors: New York Metro Area
- New Jersey Monthly: Top Doctors
- Fellow
- Fellow (FAAD)
- Fellow (FACR)
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
New York Presbyterian Hospital - Cornell Campus -
Weill Cornell Medical College of Cornell University
Hospital
-
Tufts Medical Center
Drug Facts
| NPI NUMBER | 1275581407 | |
| NPPES Provider LastName | GOTTLIEB | |
| NPPES Provider FirstName | ALICE | |
| NPPES Provider ZIPCode | 02111 | |
| NPPES Provider State | MA | |
| Specialty Description | Dermatology | |
| Total Claim Count | 85.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1275581407 |
| Last Name Of The Provider | GOTTLIEB |
| First Name Of The Provider | ALICE |
| View All |
Similar Doctors
|
|
Dr. Ernesto Gonzalez-Martinez, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zachary S. Wallace, MD |
|
|
Dr. Vivian P. Bykerk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sabina Bis, MD |
|
|
Dr. Maryanne Makredes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vasileios Kyttaris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Connie Chung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sonali P. Desai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ritu Valiyil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Connie C. Tam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Kalish, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace H. Lo, MD |
|
|
Dr. Yunyoung C. Chang, MD |
|
|
Dr. Afnan Hasanain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Damstetter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alicia Rodriguez-Pla, MD |
|
|
Dr. Sarah J. Hahn, MD |
|
|
Dr. Amy Y. Chen, MD |